The overexpression of ST3GAL1 was found to increase paclitaxel resistance in ovarian cancer, while the downregulation of ST3GAL1 reduced paclitaxel resistance in vitro in cells, as well as reducing the therapeutic effect of paclitaxel on tumor growth in mice [130]. Here, ST3GAL1 is linked to ovarian carcinoma.